ATE494002T1 - Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü - Google Patents

Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü

Info

Publication number
ATE494002T1
ATE494002T1 AT03760322T AT03760322T ATE494002T1 AT E494002 T1 ATE494002 T1 AT E494002T1 AT 03760322 T AT03760322 T AT 03760322T AT 03760322 T AT03760322 T AT 03760322T AT E494002 T1 ATE494002 T1 AT E494002T1
Authority
AT
Austria
Prior art keywords
pyy
bowel
colitis
ulcerosal
pyyä3
Prior art date
Application number
AT03760322T
Other languages
English (en)
Inventor
Bronislava Gedulin
Andrew Young
James Paterniti
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE494002T1 publication Critical patent/ATE494002T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03760322T 2002-06-14 2003-06-13 Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü ATE494002T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38893002P 2002-06-14 2002-06-14
PCT/US2003/018657 WO2003105763A2 (en) 2002-06-14 2003-06-13 Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof

Publications (1)

Publication Number Publication Date
ATE494002T1 true ATE494002T1 (de) 2011-01-15

Family

ID=29736565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03760322T ATE494002T1 (de) 2002-06-14 2003-06-13 Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü

Country Status (6)

Country Link
US (1) US20060122106A1 (de)
EP (1) EP1549336B1 (de)
AT (1) ATE494002T1 (de)
AU (1) AU2003243545A1 (de)
DE (1) DE60335639D1 (de)
WO (1) WO2003105763A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
CA2431800C (en) 2000-12-14 2014-07-08 Amylin Pharmaceuticals, Inc. Peptide yy and peptide yy agonists for treatment of metabolic disorders
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
CA2510199A1 (en) 2002-12-17 2004-07-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
KR101078098B1 (ko) 2003-01-14 2011-10-28 아레나 파마슈티칼스, 인크. 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
BRPI0507594A (pt) 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc polipetìdeos hìbridos com propriedades selecionáveis
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
CA2560166A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
CA2559838A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
EP3000826A1 (de) 2004-12-13 2016-03-30 Amylin Pharmaceuticals, LLC Motive der bauchspeicheldrüsen-polypeptid familie, polypeptide und methoden unter verwendung derselben
EP1853627A2 (de) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip-analog und hybridpolypeptide mit auswählbaren eigenschaften
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
EP1888043A4 (de) * 2005-03-11 2010-07-28 Endo Pharmaceuticals Solutions Octreotid-formulierungen mit kontrollierter freisetzung
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
EP2108960A1 (de) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY
US8071537B2 (en) * 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
JP5536053B2 (ja) 2008-06-25 2014-07-02 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． 離型剤を有するオクトレオチドインプラント
GB0817067D0 (en) * 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
EP2477643A1 (de) 2009-09-18 2012-07-25 Novo Nordisk A/S V2-rezeptoragonisten mit langzeitwirkung
EP2498800A1 (de) 2009-11-13 2012-09-19 Novo Nordisk A/S V2-rezeptoragonisten mit langzeitwirkung
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891357A (en) * 1985-02-11 1990-01-02 University Of Florida Methods and compositions for stimulation of appetite
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4839343A (en) * 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5214066A (en) * 1990-04-18 1993-05-25 Brigham And Women's Hospital Method for producing an animal model for inflammatory bowel disease including ulcerative colitis
US6391343B1 (en) * 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
EP0692971A4 (de) * 1993-03-29 1997-11-12 Univ Cincinnati Peptid yy-analogen und verwendungen dafür
US5498531A (en) * 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5696093A (en) * 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) * 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5602024A (en) * 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5912227A (en) * 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
US20020094346A1 (en) * 1995-05-17 2002-07-18 M. D. Henry C. Lin Method and compositions for improving digestion and absorption in the small intestine
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6355478B1 (en) * 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
WO1998035957A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
JP3036480B2 (ja) * 1997-08-25 2000-04-24 日本電気株式会社 バーコード読取装置およびその焦点制御方法
US6013622A (en) * 1998-04-15 2000-01-11 Nutriceutical Technology Corporation Method of regulating appetite and metabolism
US6046179A (en) * 1998-04-17 2000-04-04 Murch; Simon Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine
EP1100530B1 (de) * 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation von beta zellen vermehrung
IE990033A1 (en) * 1999-01-15 2000-10-18 Entpr Ie Trd As Bioresearch Ie Bifidobacterium longum infantis in the treatment of inflammatory bowel disease
US7745216B2 (en) * 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6734166B1 (en) * 2000-02-08 2004-05-11 North Carolina State University Method of reducing aluminum levels in the central nervous system

Also Published As

Publication number Publication date
EP1549336A4 (de) 2008-01-02
WO2003105763A2 (en) 2003-12-24
AU2003243545A8 (en) 2003-12-31
EP1549336A2 (de) 2005-07-06
WO2003105763B1 (en) 2004-09-02
EP1549336B1 (de) 2011-01-05
US20060122106A1 (en) 2006-06-08
AU2003243545A1 (en) 2003-12-31
WO2003105763A3 (en) 2004-06-17
DE60335639D1 (de) 2011-02-17

Similar Documents

Publication Publication Date Title
ATE494002T1 (de) Prävention und/oder behandlung von colitis ulcerosa mit pyy oder pyyä3-36ü
ATE510562T1 (de) Anti-ailim antikörper zur behandlung von crohn's
GB0225475D0 (en) Therapeutic agents
DE60112957D1 (de) Sulfamide als gamma-secretase-inhibitoren
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
ATE401076T1 (de) Chinolinderivate als glucokinase liganden
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
WO2005072113A3 (en) Compositions and methods of treatment for inflammatory diseases
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
NO20015607L (no) Glukagonantagonister/inversagonister
EA200100872A1 (ru) Композиция валдекоксиба
DE60144514D1 (de) Verwendung von il-18 inhibitoren
CY1108808T1 (el) Ενωσεις μοτιλιδης
MXPA04000891A (es) Nuevos derivados de acido vinilcarboxilico y su uso como antidiabeticos.
ES2184097T3 (es) Nuevos compuestos.
PT1017404E (pt) Formulacao farmaceutica para o tratamento de doenca inflamatoria do intestino
EA200200875A1 (ru) Пролекарства производных имидазопиридина
EP1284265A4 (de) Benzothiophenderivate und deren medizinische verwendungen
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
CY1111900T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα ν-μεθυλ-d-ασπαρτικων (nmda)
EA200401395A1 (ru) Способ лечения или профилактики микробных заболеваний ногтя субъекта (варианты), композиция для местного нанесения на ноготь и способ ее получения
ATE357931T1 (de) Mittel zur prävention/behandlung entzündlicher darmerkrankungen
DE69528068D1 (de) Conagenine zur prävention und behandlung von diarrhöe
DE69918826D1 (de) Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties